skip to main content
media conference

Press Releases

  • March 19, 2019

    Response to the Federal Government's budget announcement today regarding $150M for the Marathon of Hope Cancer Centres Network

    “We are thrilled with today’s announcement by the federal government to support the creation of the Marathon of Hope Cancer Centres. Under this new Terry Fox Research Network, Canadian cancer centres, together with their research teams from coast to coast, will share data, harmonize resources and apply new technologies such as genomics, advanced imaging and artificial intelligence, so that no matter where they live in Canada, cancer patients will have access to precision medicine – so the right treatment can be given to the right patient at the right time.” – Dr. Victor Ling, TFRI President and Scientific Director

  • February 25, 2019

    Blocking Type 1 Interferon reduces negative side-effects associated with potent immunotherapy

    A group of scientists from the TFRI-funded Canadian Oncolytic Virus Consortium (COVCo) has discovered a new way to reduce negative side-effects associated with a potent form of immunotherapy by blocking the expression of Type 1 Interferon (T1IFN), a key protein of the immune system.

  • January 15, 2019

    Restoring stem cells to a fetal-like state could provide a therapeutic alternative for acute leukemias

    A team of TFRI-funded scientists in Vancouver has discovered that restoring a signaling pathway that is prevalent in fetal stem cells but dormant in adult ones may provide an alterative treatment for acute T-cell leukemia (T-ALL).

  • January 15, 2019

    CEST MRI may be able to measure patient response to chemotherapy within 24 hours after first dosage

    TFRI researchers at Sunnybrook Hospital have found that CEST MRI technology can be used to detect cancer cell death in mice within 24 hours of receiving chemotherapy, much sooner than current methods.

  • January 15, 2019

    New finding suggests that disrupting interaction between MYC and G9a could stop cancer growth

    New technology has helped a TFRI-funded multidisciplinary research team identify how MYC – a key driver of human cancer – works, cracking open the possibility for new targets and treatments to stop it in its tracks.

  • January 15, 2019

    Montreal research team identifies SREBF1 as a new, targetable regulatory pathway in prostate cancer

    The newly discovered pathway, SREBF1, was found to be directly responsible for controlling prostate cancer cell metabolism. It can be targeted with several pharmacological approaches already in use to treat other diseases.

  • January 15, 2019

    Study reveals genomic differences between long- and short- term survivors of high-grade serous ovarian cancer, advancing potential for individualized treatments

    Researchers may be one step closer to personalizing treatments for patients with high-grade serous ovarian cancer thanks to a new study that revealed several clinical and genomic biomarkers that could help predict response to standard-of-care treatment.

  • January 15, 2019

    Use of mTOR inhibitors increases efficacy of herpes virus as an oncolytic therapy

    A new study by a team of TFRI-funded scientists has found that combining a particular strain of the herpes virus with mTOR inhibitors improves viral replication within tumour cells with dysregulated protein synthesis, boosting the virus’ cancer-killing ability.

  • January 15, 2019

    Pan-Canadian prostate cancer team creates robust resource tool to help clinicians with treatment decision-making

    A pan-Canadian prostate cancer group funded by the TFRI team has created a new tissue microarray (TMA)-based resource to assist clinicians and pathologists in validating biomarkers for patients with prostate cancer.

  • January 15, 2019

    Study shows benefit of vascular normalization in OV therapy for advanced epithelial ovarian cancer

    Immunologists at the University of Guelph have discovered that normalizing blood flow into tumours improves efficacy of oncolytic viruses, departing from long-held beliefs about the benefits of acute vascular shutdown.

  • January 15, 2019

    Dr. David Eisenstat appointed Alberta Node Leader for TFRI

    The Terry Fox Research Institute is pleased to announce the appointment of Dr. David Eisenstat as its new node leader for the Province of Alberta.

  • January 14, 2019

    Researchers discover common markers of tumour hypoxia across 19 cancer types

    The study, which was partially funded by the TFRI, investigated more than 8,000 human tumours across 19 different cancer types, including prostate tumours from the Canadian Prostate Cancer Genome Network (CPC-GENE). The authors discovered common markers of hypoxia that could help predict cancer aggressiveness and inform treatment decisions.

  • December 10, 2018

    Outstanding researchers from Montreal, Halifax and Toronto receive $1.35 million to find new treatments for metastatic and ovarian cancers

    Three outstanding early-career investigators from Montreal, Halifax and Toronto will each receive $450,000 over the next three years to explore new treatments for metastatic cancers like the one Terry Fox had and identify ways that immunotherapy can help ovarian cancer patients.

  • December 03, 2018

    Identification of new lymphoma sub-group by Terry Fox Research Institute-funded cancer researchers opens door for potential new treatments for hard-to-treat cancer

    The discovery by BC researchers of a group of bad actors ‘hidden’ within a cohort of good ones may translate into new hope for cancer patients diagnosed with a type of lymphoma that doesn’t respond well to treatment.

  • November 14, 2018

    TFRI BC Node researchers present their work during 2018 BC Cancer Summit

    The Terry Fox Research Institute's BC Node will host its annual Node Day on Friday, Nov. 23, 2018 at the Sheraton Wall Centre in Vancouver.

Back to Top